Ardent Health (NYSE:ARDT) Updates FY 2026 Earnings Guidance

Ardent Health (NYSE:ARDT) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.780-1.150 for the period, compared to the consensus estimate of 1.220. The company issued revenue guidance of $6.4 billion-$6.7 billion, compared to the consensus revenue estimate of $6.5 billion.

Ardent Health Price Performance

NYSE:ARDT traded up $0.53 on Wednesday, hitting $11.28. The company had a trading volume of 385,800 shares, compared to its average volume of 461,033. The firm has a 50 day moving average of $9.86 and a two-hundred day moving average of $9.44. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of 11.95, a PEG ratio of 2.53 and a beta of 0.70. The company has a current ratio of 2.12, a quick ratio of 2.00 and a debt-to-equity ratio of 0.62. Ardent Health has a 52 week low of $7.71 and a 52 week high of $15.48.

Ardent Health (NYSE:ARDT) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.06). The business had revenue of $1.62 billion for the quarter, compared to analyst estimates of $1.59 billion. Ardent Health had a return on equity of 13.85% and a net margin of 2.09%.Ardent Health has set its FY 2026 guidance at 0.780-1.150 EPS. On average, research analysts anticipate that Ardent Health will post 1.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

ARDT has been the subject of several analyst reports. Wall Street Zen lowered shares of Ardent Health from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Royal Bank Of Canada dropped their target price on shares of Ardent Health from $13.00 to $12.00 and set an “outperform” rating on the stock in a report on Thursday, July 9th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Ardent Health in a report on Friday, June 12th. UBS Group boosted their price objective on Ardent Health from $13.00 to $13.50 and gave the company a “buy” rating in a research note on Thursday, May 7th. Finally, Truist Financial decreased their target price on Ardent Health from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. Seven analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $14.04.

Insider Buying and Selling

In other news, CFO Alfred Lumsdaine bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were bought at an average cost of $8.81 per share, for a total transaction of $88,100.00. Following the acquisition, the chief financial officer directly owned 329,183 shares in the company, valued at approximately $2,900,102.23. This trade represents a 3.13% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.90% of the company’s stock.

Institutional Trading of Ardent Health

Institutional investors and hedge funds have recently made changes to their positions in the company. Goldentree Asset Management LP lifted its position in shares of Ardent Health by 99.7% during the 4th quarter. Goldentree Asset Management LP now owns 2,303,113 shares of the company’s stock worth $20,302,000 after buying an additional 1,150,000 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in Ardent Health by 8.2% during the third quarter. Ameriprise Financial Inc. now owns 1,769,335 shares of the company’s stock worth $23,444,000 after acquiring an additional 134,513 shares during the period. Vanguard Group Inc. boosted its position in Ardent Health by 44.5% in the third quarter. Vanguard Group Inc. now owns 1,352,676 shares of the company’s stock worth $17,923,000 after purchasing an additional 416,348 shares during the last quarter. Millennium Management LLC grew its stake in Ardent Health by 6.6% in the 3rd quarter. Millennium Management LLC now owns 1,269,605 shares of the company’s stock valued at $16,822,000 after purchasing an additional 78,861 shares during the period. Finally, Bridgeway Capital Management LLC increased its position in shares of Ardent Health by 108.2% during the 4th quarter. Bridgeway Capital Management LLC now owns 946,571 shares of the company’s stock valued at $8,358,000 after purchasing an additional 491,961 shares during the last quarter.

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.